Sacubitril/valsartan and circulating neprilysin hypothesis in patients with HFpEF

被引：0
|
作者：
Santiago-Vacas, E. [1 ]
Codina, P. [1 ]
Domingo, M. [1 ]
De Antonio, M. [1 ]
Zamora, E. [1 ]
Santesmases, J. [1 ]
Julian, M. T. [1 ]
Diez-Quevedo, C. [1 ]
Troya, M., I [1 ]
Boldo, M. [1 ]
Altimir, S. [1 ]
Nunez, J. [2 ]
Gonzalez, B. [1 ]
Lupon, J. [1 ]
Bayes-Genis, A. [1 ]
机构：
[1] Germans Trias & Pujol Hosp, Badalona, Spain
[2] Univ Gen Hosp Valencia, Valencia, Spain
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：860 / 860
页数：1
相关论文
共 50 条
  • [1] Circulating neprilysin hypothesis in HFpEF and sacubitril/valsartan
    Santiago-Vacas, E.
    De Antonio, M.
    Codina, P.
    Domingo, M.
    Zamora, E.
    Santesmases, J.
    Alonso, N.
    Diez-Quevedo, C.
    Troya, M. I.
    Boldo, M.
    Altimir, S.
    Nunez, J.
    Gonzalez, B.
    Josep Lupon, J.
    Bayes-Genis, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 87 - 88
  • [2] Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
    Lupon, Josep
    Santiago-Vacas, Evelyn
    Cediel, German
    Codina, Pau
    Domingo, Mar
    Revuelta-Lopez, Elena
    Zamora, Elisabet
    Spitaleri, Giosafat
    Santesmases, Javier
    Nunez, Julio
    Bayes-Genis, Antoni
    PLOS ONE, 2021, 16 (05):
  • [3] Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
    Guo, Yanhong
    Ren, Mingjing
    Wang, Tingting
    Wang, Yulin
    Pu, Tian
    Li, Xiaodan
    Yu, Lu
    Wang, Liuwei
    Liu, Peipei
    Tang, Lin
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [4] Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF
    Cunningham, Jonathan W.
    Claggett, Brian L.
    O'Meara, Eileen
    Pfeffer, Marc A.
    Prescott, Margaret F.
    Shah, Sanjiv J.
    Redfield, Margaret M.
    Zannad, Faiez
    Chiang, Lu-May
    Rizkala, Adel R.
    Shi, Victor C.
    Lefkowitz, Martin P.
    Rouleau, Jean
    McMurray, John J. V.
    Solomon, Scott D.
    Zile, Michael R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (05) : 503 - 514
  • [5] Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
    Dargad, Ramesh R.
    Prajapati, Mahesh R.
    Dargad, Rohit R.
    Parekh, Jai D.
    INDIAN HEART JOURNAL, 2018, 70 : S102 - S110
  • [6] Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
    Brioschi, Maura
    D'Alessandra, Yuri
    Mapelli, Massimo
    Mattavelli, Irene
    Salvioni, Elisabetta
    Eligini, Sonia
    Mallia, Alice
    Ricci, Veronica
    Gianazza, Erica
    Ghilardi, Stefania
    Agostoni, Piergiuseppe
    Banfi, Cristina
    BIOMEDICINES, 2023, 11 (04)
  • [7] Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives
    Gori, Mauro
    D'Elia, Emilia
    Senni, Michele
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 281 : 158 - 165
  • [8] Sacubitril/Valsartan as Antifibrotic Drug Rejuvenating the Fibrosed HFpEF Heart
    Bayes-Genis, Antoni
    Nunez, Julio
    Lupon, Josep
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (05) : 515 - 517
  • [9] The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
    Jhund, Pardeep S.
    McMurray, John J. V.
    HEART, 2016, 102 (17) : 1342 - 1347
  • [10] Angiotensin Neprilysin Inhibition for Patients With Heart Failure What If Sacubitril/Valsartan Were a Treatment for Cancer?
    Packer, Milton
    JAMA CARDIOLOGY, 2016, 1 (09) : 971 - 972
12345